Myriad Genetics Financials - Benzinga

Myriad Genetics Inc

MYGNNASDAQ

Trade with Public

Trade with Public

$3.36

0.175.33%

At close: Sep 10, 5:00 PM EST

$3.31

-0.0487-1.45%

After Hours: 7:14 PM EST

Overview News Earnings Forecast Events Price TargetsFinancialsSentiment Ownership Compare Options Stock Report

Myriad Genetics Financials

Myriad Genetics (MYGN) financial statements — income, revenue, gross margin and key metrics.

Earnings & Guidance News

Myriad Genetics Stock Drops Sharply After Hours: What Investors Need to Know

Myriad Genetics stock fell after hours after weak Q2 results, lower guidance and an operating loss.

Tanya Rawat

PRO
Myriad Genetics Lowers FY2026 Sales Guidance from $860.000M-$880.000M to $770.000M-$790.000M vs $863.568M Est

Myriad Genetics (NASDAQ:MYGN) lowers FY2026 sales outlook from $860.000 million-$880.000 million to $770.000 million-$790.000 million vs $863.568 million estimate.

Benzinga Newsdesk

PRO
Myriad Genetics Q2 Adj. EPS $(0.25) Misses $(0.06) Estimate, Sales $190.700M Miss $206.029M Estimate

Benzinga Newsdesk

PRO
Myriad Genetics Affirms FY2026 Sales Guidance of $860.000M-$880.000M vs $864.099M Est

Myriad Genetics (NASDAQ:MYGN) affirms FY2026 sales outlook from $860.000 million-$880.000 million to $860.000 million-$880.000 million vs $864.099 million estimate.

Benzinga Newsdesk

PRO
Myriad Genetics Q1 Adj. EPS $(0.09) Misses $(0.07) Estimate, Sales $200.400M Miss $202.484M Estimate

Myriad Genetics (NASDAQ:MYGN) reported quarterly losses of $(0.09) per share which missed the analyst consensus estimate of $(0.07) by 28.57 percent. This is a 200 percent decrease over losses of $(0.03) per share from

Benzinga Newsdesk

Earnings Scheduled For May 5, 2026

Benzinga Insights